These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 19333003)

  • 1. Loss of BRCA1 function increases the antitumor activity of cisplatin against human breast cancer xenografts in vivo.
    Tassone P; Di Martino MT; Ventura M; Pietragalla A; Cucinotto I; Calimeri T; Bulotta A; Neri P; Caraglia M; Tagliaferri P
    Cancer Biol Ther; 2009 Apr; 8(7):648-53. PubMed ID: 19333003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells.
    Tassone P; Tagliaferri P; Perricelli A; Blotta S; Quaresima B; Martelli ML; Goel A; Barbieri V; Costanzo F; Boland CR; Venuta S
    Br J Cancer; 2003 Apr; 88(8):1285-91. PubMed ID: 12698198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential sensitivity of BRCA1-mutated HCC1937 human breast cancer cells to microtubule-interfering agents.
    Tassone P; Blotta S; Palmieri C; Masciari S; Quaresima B; Montagna M; D'Andrea E; Eramo OP; Migale L; Costanzo F; Tagliaferri P; Venuta S
    Int J Oncol; 2005 May; 26(5):1257-63. PubMed ID: 15809716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular responses of BRCA1-defective HCC1937 breast cancer cells induced by the antimetastasis ruthenium(II) arene compound RAPTA-T.
    Nhukeaw T; Hongthong K; Dyson PJ; Ratanaphan A
    Apoptosis; 2019 Aug; 24(7-8):612-622. PubMed ID: 31016421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular trail for the anticancer behavior of a novel copper carbohydrazone complex in BRCA1 mutated breast cancer.
    Nair RS; Potti ME; Thankappan R; Chandrika SK; Kurup MR; Srinivas P
    Mol Carcinog; 2017 May; 56(5):1501-1514. PubMed ID: 28052399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential Cytotoxicity, Cellular Uptake, Apoptosis and Inhibition of BRCA1 Expression of BRCA1-Defective and Sporadic Breast Cancer Cells Induced by an Anticancer Ruthenium(II)-Arene Compound, RAPTA-EA1.
    Ratanaphan A; Nhukeaw T; Hongthong K; Dyson PJ
    Anticancer Agents Med Chem; 2017; 17(2):212-220. PubMed ID: 27039925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
    Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
    Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Novel Ribonucleotide Reductase Inhibitor COH29 Inhibits DNA Repair In Vitro.
    Chen MC; Zhou B; Zhang K; Yuan YC; Un F; Hu S; Chou CM; Chen CH; Wu J; Wang Y; Liu X; Smith DL; Li H; Liu Z; Warden CD; Su L; Malkas LH; Chung YM; Hu MC; Yen Y
    Mol Pharmacol; 2015 Jun; 87(6):996-1005. PubMed ID: 25814515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective mode of action of plumbagin through BRCA1 deficient breast cancer stem cells.
    Somasundaram V; Hemalatha SK; Pal K; Sinha S; Nair AS; Mukhopadhyay D; Srinivas P
    BMC Cancer; 2016 May; 16():336. PubMed ID: 27229859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cationic liposome codelivering PI3K pathway regulator improves the response of BRCA1-deficient breast cancer cells to PARP1 inhibition.
    Zhang H; Yu N; Chen Y; Yan K; Wang X
    J Cell Biochem; 2019 Aug; 120(8):13037-13045. PubMed ID: 30873673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular responses of BRCA1-defective and triple-negative breast cancer cells and in vitro BRCA1 interactions induced by metallo-intercalator ruthenium(II) complexes containing chloro-substituted phenylazopyridine.
    Nhukeaw T; Temboot P; Hansongnern K; Ratanaphan A
    BMC Cancer; 2014 Feb; 14():73. PubMed ID: 24507701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteomic Profiling of β-hCG-Induced Spheres in BRCA1 Defective Triple Negative Breast Cancer Cells.
    Sengodan SK; Rajan A; Hemalatha SK; Nadhan R; Jaleel A; Srinivas P
    J Proteome Res; 2018 Jan; 17(1):276-289. PubMed ID: 29028349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthetically Lethal BMN 673 (Talazoparib) Loaded Solid Lipid Nanoparticles for BRCA1 Mutant Triple Negative Breast Cancer.
    Guney Eskiler G; Cecener G; Egeli U; Tunca B
    Pharm Res; 2018 Sep; 35(11):218. PubMed ID: 30255456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic exploitation of tumor cell defects in homologous recombination.
    Powell SN; Kachnic LA
    Anticancer Agents Med Chem; 2008 May; 8(4):448-60. PubMed ID: 18473729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRCA1 mutations drive oxidative stress and glycolysis in the tumor microenvironment: implications for breast cancer prevention with antioxidant therapies.
    Martinez-Outschoorn UE; Balliet R; Lin Z; Whitaker-Menezes D; Birbe RC; Bombonati A; Pavlides S; Lamb R; Sneddon S; Howell A; Sotgia F; Lisanti MP
    Cell Cycle; 2012 Dec; 11(23):4402-13. PubMed ID: 23172369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. iPSC-Derived Hereditary Breast Cancer Model Reveals the
    Portier L; Desterke C; Chaker D; Oudrhiri N; Asgarova A; Dkhissi F; Turhan AG; Bennaceur-Griscelli A; Griscelli F
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33513753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition.
    Sun C; Li N; Yang Z; Zhou B; He Y; Weng D; Fang Y; Wu P; Chen P; Yang X; Ma D; Zhou J; Chen G
    J Natl Cancer Inst; 2013 Nov; 105(22):1750-8. PubMed ID: 24168967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1.
    Zhu Y; Liu Y; Zhang C; Chu J; Wu Y; Li Y; Liu J; Li Q; Li S; Shi Q; Jin L; Zhao J; Yin D; Efroni S; Su F; Yao H; Song E; Liu Q
    Nat Commun; 2018 Apr; 9(1):1595. PubMed ID: 29686231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A DNA repair BRCA1 estrogen receptor and targeted therapy in breast cancer.
    Ratanaphan A
    Int J Mol Sci; 2012 Nov; 13(11):14898-916. PubMed ID: 23203101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-218 regulates cisplatin chemosensitivity in breast cancer by targeting BRCA1.
    He X; Xiao X; Dong L; Wan N; Zhou Z; Deng H; Zhang X
    Tumour Biol; 2015 Mar; 36(3):2065-75. PubMed ID: 25394901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.